Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare | Zendy

Jifang Zhou | Zendy; Karen Sweiss | Zendy; Edith A. Nutescu | Zendy; Jin Han | Zendy; Pritesh Patel | Zendy; Naomi Y. Ko | Zendy; Todd A. Lee | Zendy; Brian C.H. Chiu | Zendy; Gregory S. Calip | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare

Author(s) -

Jifang Zhou,

Karen Sweiss,

Edith A. Nutescu,

Jin Han,

Pritesh Patel,

Naomi Y. Ko,

Todd A. Lee,

Brian C.H. Chiu,

Gregory S. Calip

Publication year - 2021

Publication title -

jco oncology practice

Language(s) - English

Resource type - Journals

eISSN - 2688-1535

pISSN - 2688-1527

DOI - 10.1200/op.20.00479

Subject(s) - medicine , discontinuation , bisphosphonate , retrospective cohort study , pacific islanders , multiple myeloma , population , hazard ratio , cohort , surgery , osteoporosis , confidence interval , environmental health

Intravenous (IV) bisphosphonates reduce the risk of skeletal-related events in patients with multiple myeloma (MM). However, data describing racial differences in IV bisphosphonate utilization outside of clinical trial settings are limited. We evaluated population-level IV bisphosphonate initiation and discontinuation among patients of age ≥ 65 years with MM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research